4.4 Article

Connective tissue disease-associated interstitial lung disease

期刊

PULMONOLOGY
卷 28, 期 2, 页码 113-118

出版社

ELSEVIER
DOI: 10.1016/j.pulmoe.2020.01.004

关键词

Connective tissue disease; Interstitial lung disease; Rheumatoid arthritis; Systemic sclerosis; Tocilizumab; Nintedanib

向作者/读者索取更多资源

Connective tissue diseases (CTD) are frequently associated with interstitial lung disease (ILD), significantly impacting morbidity and mortality. This study analyzed the experience of an autoimmune specialized unit in treating CTD-ILD and characterized the patient population based on common diseases, imaging patterns, lung function tests results, serology, and treatment. It also assessed mortality and mortality predictors, with pulmonary hypertension identified as the most important predictor. The study highlights the importance of chest physicians in these specialized units.
Background: Connective tissue diseases (CTD) are frequently associated with interstitial lung disease (ILD), significantly impacting their morbidity and mortality. Aim: Analyze the experience of an autoimmune specialized unit on treating CTD-ILD and characterize the population based on most frequent diseases, imaging patterns, lung function tests results, serology and treatment. Assess mortality and mortality predictors in these patients. Methods: Retrospective, descriptive and statistical analysis of the CTD-ILD patients followed up at an autoimmune diseases unit during a 6-year period. Results: Over the study period, 75 patients with CTD-ILD were treated with a mean follow-up of 49 +/- 31 months. The most frequent CTD were systemic sclerosis and rheumatoid arthritis. ILD was diagnosed prior to CTD in 8% of patients and concomitantly in 35%. Nonspecific interstitial pneumonia was the CT pattern in 60% and 35% had an isolated diminished DLCO on lung function tests. Pulmonary hypertension was present in 12% and it was the single most important mortality predictor (OR 14.41, p = 0.006). Corticosteroids are the mainstay of treatment but biologics were prescribed in 39% of the patients (mostly tocilizumab and rituximab). Two scleroderma patients were recently treated with nintedanib. Conclusions: ILD is a potential complication of every CTD and can impose a dramatic burden on these patients. The clinical relevance of ILD together with their early expression in the course of the disease underlines the importance of the presence of chest physicians in these units. (C) 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier Espana, S.L.U.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据